PURPOSE: The effects of a low-fat diet or a low-fat diet with the addition of a soy supplement were investigated in a pilot Phase II study for asymptomatic, hormonally naive prostate cancer patients with rising prostate-specific antigen (PSA) levels. EXPERIMENTAL DESIGN: A two-step intervention was implemented. During step 1 patients were begun on a low-fat diet with a goal to reduce fat intake to 15% of total daily calories. On PSA progression, a soy protein supplement was added to the diet (step 2). The primary end point was PSA reduction by 50%. Secondary end points were PSA doubling time and time to progression (TTP). Serum was analyzed for changes in the sex hormone and insulin-like growth factor (IGF-I) axes. RESULTS: Among 18 evaluable patients, (median follow-up on study 10.5 months), no patient on either step had a PSA reduction by 50% at any time. There was a trend toward a longer PSA doubling time (P = 0.06) and a prolongation in estimated median TTP of approximately 3 months (P = 0.018) during step 2 compared with step 1 of the study. During step 1, free testosterone levels decreased by 5% (P < 0.01), and during step 2, IGF-I levels increased by 22% (P = 0.02). CONCLUSIONS: A low-fat diet with the subsequent addition of a soy supplement did not result in a significant decline in PSA levels. The addition of soy protein had a modest effect on TTP. A potentially undesirable effect associated with the administration of soy was an increase in IGF-I serum levels.
PURPOSE: The effects of a low-fat diet or a low-fat diet with the addition of a soy supplement were investigated in a pilot Phase II study for asymptomatic, hormonally naive prostate cancerpatients with rising prostate-specific antigen (PSA) levels. EXPERIMENTAL DESIGN: A two-step intervention was implemented. During step 1 patients were begun on a low-fat diet with a goal to reduce fat intake to 15% of total daily calories. On PSA progression, a soy protein supplement was added to the diet (step 2). The primary end point was PSA reduction by 50%. Secondary end points were PSA doubling time and time to progression (TTP). Serum was analyzed for changes in the sex hormone and insulin-like growth factor (IGF-I) axes. RESULTS: Among 18 evaluable patients, (median follow-up on study 10.5 months), no patient on either step had a PSA reduction by 50% at any time. There was a trend toward a longer PSA doubling time (P = 0.06) and a prolongation in estimated median TTP of approximately 3 months (P = 0.018) during step 2 compared with step 1 of the study. During step 1, free testosterone levels decreased by 5% (P < 0.01), and during step 2, IGF-I levels increased by 22% (P = 0.02). CONCLUSIONS: A low-fat diet with the subsequent addition of a soy supplement did not result in a significant decline in PSA levels. The addition of soy protein had a modest effect on TTP. A potentially undesirable effect associated with the administration of soy was an increase in IGF-I serum levels.
Authors: Jennifer H Ahn-Jarvis; Steven K Clinton; Elizabeth M Grainger; Kenneth M Riedl; Steven J Schwartz; Mei-Ling T Lee; Raul Cruz-Cano; Gregory S Young; Gregory B Lesinski; Yael Vodovotz Journal: Cancer Prev Res (Phila) Date: 2015-08-14
Authors: Maarten C Bosland; Ikuko Kato; Anne Zeleniuch-Jacquotte; Joanne Schmoll; Erika Enk Rueter; Jonathan Melamed; Max Xiangtian Kong; Virgilia Macias; Andre Kajdacsy-Balla; L H Lumey; Hui Xie; Weihua Gao; Paul Walden; Herbert Lepor; Samir S Taneja; Carla Randolph; Michael J Schlicht; Hiroko Meserve-Watanabe; Ryan J Deaton; Joanne A Davies Journal: JAMA Date: 2013-07-10 Impact factor: 56.272
Authors: Christopher D Gardner; Beibei Oelrich; Jenny P Liu; David Feldman; Adrian A Franke; James D Brooks Journal: Prostate Date: 2009-05-15 Impact factor: 4.104
Authors: Srilatha Swami; Aruna V Krishnan; Jacqueline Moreno; Rumi S Bhattacharyya; Christopher Gardner; James D Brooks; Donna M Peehl; David Feldman Journal: Int J Cancer Date: 2009-05-01 Impact factor: 7.396
Authors: J Kellogg Parsons; John P Pierce; James Mohler; Electra Paskett; Sin-Ho Jung; Peter Humphrey; John R Taylor; Vicky A Newman; Leslie Barbier; Cheryl L Rock; James Marshall Journal: Contemp Clin Trials Date: 2014-05-13 Impact factor: 2.226